Delaforge M - Search Results

1

Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450. Particular involvement of CYP 2D.

Delaforge M, Jaouen M, Bouille G. Delaforge M, et al. Environ Toxicol Pharmacol. 1999 Jul;7(3):153-8. doi: 10.1016/s1382-6689(99)00007-1. Environ Toxicol Pharmacol. 1999. PMID: 21781921

2

Intramolecular hydrogen bonding as a determinant of the inhibitory potency of N-unsubstituted imidazole derivatives towards mammalian hemoproteins.

Perrin L, André F, Aninat C, Ricoux R, Mahy JP, Shangguan N, Joullié MM, Delaforge M. Perrin L, et al. Among authors: delaforge m. Metallomics. 2009 Mar;1(2):148-56. doi: 10.1039/b817743k. Epub 2008 Nov 27. Metallomics. 2009. PMID: 21305108

3

Metabolism of phenylahistin enantiomers by cytochromes P450: a possible explanation for their different cytotoxicity.

Perrin L, Aninat C, Hamon V, Hayashi Y, Abadie C, Heyd B, André F, Delaforge M. Perrin L, et al. Among authors: delaforge m. Drug Metab Dispos. 2008 Nov;36(11):2381-92. doi: 10.1124/dmd.107.019919. Epub 2008 Aug 7. Drug Metab Dispos. 2008. PMID: 18687804

4

In vivo effects of zearalenone on the expression of proteins involved in the detoxification of rat xenobiotics.

Duca RC, Mabondzo A, Bravin F, Delaforge M. Duca RC, et al. Among authors: delaforge m. Environ Toxicol. 2012 Feb;27(2):98-108. doi: 10.1002/tox.20617. Epub 2010 Jul 6. Environ Toxicol. 2012. PMID: 20607812

5

Improvement of cyclophosphamide activation by CYP2B6 mutants: from in silico to ex vivo.

Nguyen TA, Tychopoulos M, Bichat F, Zimmermann C, Flinois JP, Diry M, Ahlberg E, Delaforge M, Corcos L, Beaune P, Dansette P, André F, de Waziers I. Nguyen TA, et al. Among authors: delaforge m. Mol Pharmacol. 2008 Apr;73(4):1122-33. doi: 10.1124/mol.107.042861. Epub 2008 Jan 22. Mol Pharmacol. 2008. PMID: 18212249

6

In vitro cytochrome p450 formation of a mono-hydroxylated metabolite of zearalenone exhibiting estrogenic activities: possible occurrence of this metabolite in vivo.

Bravin F, Duca RC, Balaguer P, Delaforge M. Bravin F, et al. Among authors: delaforge m. Int J Mol Sci. 2009 Apr 21;10(4):1824-37. doi: 10.3390/ijms10041824. Int J Mol Sci. 2009. PMID: 19468341 Free PMC article.

7

Cytochrome P450-mediated oxidation of glucuronide derivatives: example of estradiol-17beta-glucuronide oxidation to 2-hydroxy-estradiol-17beta-glucuronide by CYP 2C8.

Delaforge M, Pruvost A, Perrin L, André F. Delaforge M, et al. Drug Metab Dispos. 2005 Mar;33(3):466-73. doi: 10.1124/dmd.104.002097. Epub 2004 Dec 17. Drug Metab Dispos. 2005. PMID: 15608133

8

Inhibitory effects of roquefortine on hepatic cytochromes P450.

Aninat C, Delaforge M. Aninat C, et al. Among authors: delaforge m. Adv Exp Med Biol. 2001;500:331-4. doi: 10.1007/978-1-4615-0667-6_52. Adv Exp Med Biol. 2001. PMID: 11764963 No abstract available.

9

Molecular requirements for inhibition of cytochrome p450 activities by roquefortine.

Aninat C, Hayashi Y, André F, Delaforge M. Aninat C, et al. Among authors: delaforge m. Chem Res Toxicol. 2001 Sep;14(9):1259-65. doi: 10.1021/tx015512l. Chem Res Toxicol. 2001. PMID: 11559041

10

Recognition and oxidative metabolism of cyclodipeptides by hepatic cytochrome P450.

Delaforge M, Bouillé G, Jaouen M, Jankowski CK, Lamouroux C, Bensoussan C. Delaforge M, et al. Peptides. 2001 Apr;22(4):557-65. doi: 10.1016/s0196-9781(01)00364-3. Peptides. 2001. PMID: 11311724

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results